Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
31.12
-0.14 (-0.45%)
Aug 21, 2025, 10:31 AM - Market open

Company Description

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria.

The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.

Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc.
Vaxcyte logo
CountryUnited States
Founded2013
IPO DateJun 12, 2020
IndustryBiotechnology
SectorHealthcare
Employees414
CEOGrant Pickering

Contact Details

Address:
825 Industrial Road, Suite 300
San Carlos, California 94070
United States
Phone650 837 0111
Websitevaxcyte.com

Stock Details

Ticker SymbolPCVX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001649094
CUSIP Number92243G108
ISIN NumberUS92243G1085
Employer ID46-4233385
SIC Code2836

Key Executives

NamePosition
Grant E. Pickering M.B.A.Co-Founder, Chief Executive Officer and Director
Andrew L. Guggenhime M.B.A.President and Chief Financial Officer
James Wassil M.B.A., M.S.Executive Vice President and Chief Operating Officer
Mikhail Eydelman J.D.Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Dr. Jeff Fairman Ph.D.Co-Founder and Vice President of Research
Whitney JonesChief People Officer
Janet GraesserSenior Vice President of Corporate Affairs
Harp Dhaliwal M.B.A.Chief Technical Operations Officer
Sam IkiSenior Vice President of Project Management
Elvia CowanSenior Vice President of Finance

Latest SEC Filings

DateTypeTitle
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 6, 202510-QQuarterly Report
Aug 6, 20258-KCurrent Report
Aug 6, 2025SCHEDULE 13G/AFiling
Jun 17, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 14, 2025UPLOADFiling
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
May 7, 2025SCHEDULE 13G/AFiling